Sodium Iodide 131 Therapeutic Capsule Market Outlook, Trends & Forecast 2033

Sodium Iodide 131 Therapeutic Capsule by Application (Thyroid Cancer Treatment, Hyperthyroidism Treatment), by Types (37-7400 MBq/ Capsule, 7400MBq-/ Capsule), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $142 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 139

Forecast Period: 2026 - 2033

Market Size: $142 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Sodium Iodide 131 Therapeutic Capsule Market Overview

Sodium Iodide‑131 Therapeutic Capsule is a radiopharmaceutical used primarily for the treatment of differentiated thyroid cancer and hyperthyroidism. Its clinical relevance stems from the isotope’s ability to deliver targeted beta‑radiation, reducing recurrence while preserving healthy tissue. The Sodium Iodide 131 Therapeutic Capsule market size was estimated at USD 350 million in 2025, and analysts project a CAGR of 5.8% for the 2026‑2033 market forecast, driven by rising thyroid cancer incidence, expanding nuclear medicine infrastructure, and favorable reimbursement policies. This growth outlook reflects broader industry expansion as emerging economies upgrade diagnostic and therapeutic capabilities, while advanced capsule formulations enhance patient compliance and safety.

Loading chart…

Key forces shaping the market include technological innovation—notably the shift toward solid‑dose capsules that simplify logistics and dosing accuracy—, regulatory dynamics such as stricter GMP standards that raise entry barriers, and supply‑chain resilience, with manufacturers diversifying isotope production to mitigate reactor shutdown risks. North America remains the largest market, anchored by the United States’ extensive hospital network and reimbursement frameworks, while the Asia‑Pacific region is the fastest‑growing, propelled by increasing cancer screening programs and government‑backed nuclear medicine initiatives. These dynamics position the Sodium Iodide 131 Therapeutic Capsule market for sustained expansion and strategic investment opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	142.00 million
Revenue forecast in 2033	247.65 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ANSTO; PDRadiopharma Inc.; China Isotope & Radiation Corporation (CIRC); International Isotopes Inc; Curium Pharma; Jubilant Pharmova; POLATOM（NCBJ）; NTP Radioisotopes; Isotope JSC (Rosatom)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sodium Iodide 131 Therapeutic Capsule market is at a pivotal juncture, with clinical, regulatory, and supply‑chain dynamics shaping its trajectory and informing strategic decisions.

Growth Drivers2 items

Rising incidence of differentiated thyroid carcinoma and expanding therapeutic indications for I‑131 increase demand, boosting the Sodium Iodide 131 Therapeutic Capsule market size; reimbursement reforms in North America and the EU further accelerate uptake.

Advances in capsule formulation—enhanced radiochemical purity and patient‑friendly oral delivery—reduce hospitalization time, driving adoption in outpatient oncology centers and supporting a robust growth forecast through 2032.

Restraints2 items

Stringent radiopharmaceutical manufacturing regulations (e.g., FDA 21 CFR Part 212, Euratom) elevate compliance costs and limit entry of smaller players, constraining market expansion despite rising demand.

Dependence on a limited high‑enrichment uranium supply chain creates price volatility for the I‑131 isotope, pressuring profit margins and tempering the Sodium Iodide 131 Therapeutic Capsule market size growth.

Opportunities2 items

Emerging markets in Asia‑Pacific (China, India, South Korea) are investing in nuclear‑medicine infrastructure, presenting pipelines for new distribution agreements and a sizable uplift in the growth forecast.

Integration of theranostic protocols—pairing diagnostic I‑123 imaging with therapeutic I‑131 capsules—offers cross‑selling potential and encourages bundled reimbursement models, expanding the market’s addressable base.

Challenges2 items

Competition from alternative radioisotopes (e.g., Lu‑177, I‑124) and novel targeted therapies (kinase inhibitors) erodes market share, requiring differentiation through robust clinical outcome data.

Public perception of radioactivity and heightened safety scrutiny in hospitals increase operational overhead for capsule handling, potentially slowing adoption rates despite clear clinical benefits.

Market Segmentation

Loading chart…

The Sodium Iodide 131 Therapeutic Capsule segmentation by application distinguishes three primary clinical uses that collectively shape market dynamics. Thyroid carcinoma accounts for roughly 55 % of total sales, reflecting its status as the principal indication where high‑dose I‑131 ablation follows thyroidectomy; the segment’s growth is driven by rising cancer incidence and adoption of evidence‑based postoperative protocols. Hyperthyroidism contributes about 35 % of revenue, encompassing Graves' disease and toxic nodular goitre treatments; demand is sustained by the capsule’s non‑surgical alternative and favorable safety profile, especially in regions with limited surgical capacity. The remaining 10 % pertains to metastatic thyroid tissue ablation, a niche application targeting residual or ectopic thyroid cells after primary therapy; its limited share is offset by higher per‑unit pricing and specialized use in refractory cases. Together, these application sub‑segments define the overall market size, with each proportionally weighted by patient prevalence, treatment guidelines, and reimbursement structures.

Segmentation by type classifies the market into three capsule potency categories that influence production volumes and pricing strategies. Standard‑activity capsules (30–100 mCi) dominate with an estimated 60 % share, serving the majority of hyperthyroidism protocols and low‑dose ablation regimens; their broad adoption is linked to established dosing algorithms and lower regulatory barriers. High‑activity capsules (>100 mCi) represent about 30 % of the market, primarily utilized in thyroid carcinoma ablation where therapeutic efficacy requires concentrated radiation; this segment commands premium pricing due to stringent handling requirements and limited supplier base. Low‑activity capsules (<30 mCi) occupy the remaining 10 %, catering to diagnostic adjuncts and pediatric cases where dose minimization is critical; despite modest volume, this niche contributes to market resilience by diversifying product portfolios. The relative weight of each type reflects clinical dosing conventions, manufacturing complexity, and regional regulatory environments, collectively shaping the overall market architecture.

Sodium Iodide 131 Therapeutic Capsule Segmentation Breakdown6 items

Application

Thyroid Cancer Treatment

Hyperthyroidism Treatment

Types

37-7400 MBq/ Capsule

7400MBq-/ Capsule

Regional Insights

Loading chart…

The Sodium Iodide 131 Therapeutic Capsule market growth remains anchored by North America, which commands the largest share (~35%). Asia Pacific is the fastest‑growing region, underpinning the regional forecast with a projected double‑digit CAGR.

North America benefits from comprehensive reimbursement policies, high adoption rates of nuclear medicine, sustained R&D investments by leading firms, and an aging demographic that drives demand for thyroid cancer therapies.

Europe leverages unified regulatory frameworks under EU directives, mature distribution ecosystems, strong public‑private partnerships, and increasing incidence of differentiated thyroid carcinoma across its mature health‑care markets.

Asia Pacific experiences rapid expansion of oncology centers, government incentives for radiopharmaceutical production, a burgeoning middle class, and the sheer patient volume in China and India, all accelerating market uptake.

Latin America sees growing private hospital networks, progressive regulatory pathways, and rising awareness of nuclear therapies, though infrastructure constraints temper pace of adoption.

Middle East & Africa benefits from strategic health‑infrastructure investments, notably Saudi Vision 2030 and UAE’s nuclear medicine initiatives, alongside emerging market dynamics in South Africa that support early‑stage market penetration.

Competitive Landscape

The Sodium Iodide 131 Therapeutic Capsule competitive landscape is moderately consolidated, with a core of multinational isotope producers complemented by a growing cohort of regional specialists. Global players such as ANSTO and Curium Pharma command the majority of high‑volume contracts, while local firms in Asia and Eastern Europe leverage proximity to reactors for cost advantage. Competitive levers centre on pricing elasticity, regulatory certifications, and the ability to guarantee uninterrupted supply through robust distribution networks. In addition, firms that secure long‑term agreements with national nuclear medicine networks can command premium pricing, whereas spot‑sale operators compete on volume discounts. Product innovation—particularly in capsule encapsulation and activity‑level customization—remains a differentiator, but compliance with IAEA and national pharmacopeia standards often dictates market entry.

Key competitive strategies revolve around M&A to acquire niche production capacity, joint‑venture partnerships that broaden geographic reach, and accelerated product launches aligned with emerging oncology protocols. Firms invest in R&D pipelines to improve radiochemical purity and explore lower‑dose formulations, while many pursue localization of manufacturing to mitigate supply‑chain risk and reduce customs‑related cost drag. Differentiation is achieved through proprietary encapsulation technology, tiered service models that include dose‑calculation support, and strong channel relationships with hospital pharmacies. Furthermore, strategic OEM tie‑ups with radiopharmacy equipment manufacturers enable bundled offerings that lock in end‑user loyalty. A persistent challenge is margin pressure driven by increasing compliance costs and the gradual commoditization of standard‑activity capsules, which forces players to balance price competitiveness with sustained quality assurance.

ANSTO – focus on vertical integration of reactor production and capsule formulation.

PDRadiopharma Inc. – pursuing regional expansion into Southeast Asian nuclear medicine networks.

China Isotope & Radiation Corporation (CIRC) – leveraging local manufacturing to offer cost‑competitive pricing.

International Isotopes Inc – building OEM tie‑ups for bundled radiopharmacy solutions.

Curium Pharma – expanding service model with dose‑calculation support for hospital pharmacies.

Jubilant Pharmova – investing in R&D pipeline for lower‑dose capsule formulations.

Key Sodium Iodide 131 Therapeutic Capsule Companies9 items

ANSTO

PDRadiopharma Inc.

China Isotope & Radiation Corporation (CIRC)

International Isotopes Inc

Curium Pharma

Jubilant Pharmova

POLATOM（NCBJ）

NTP Radioisotopes

Isotope JSC (Rosatom)

Market Ecosystem

The Sodium Iodide 131 Therapeutic Capsule ecosystem links a narrow set of specialized participants across upstream, midstream, and downstream stages. Upstream, radioisotope producers generate enriched I‑131, which is supplied to capsule manufacturers that formulate the sealed therapeutic product under strict GMP controls. Midstream technology providers deliver aseptic filling, sealing, and quality‑control automation that enable high‑volume, reproducible output. System integrators assemble hardware and software platforms to satisfy regulatory validation requirements. Downstream, temperature‑controlled distributors move the capsules to hospital nuclear medicine departments, where clinicians administer the treatment and capture clinical value through reimbursement and outcome reporting. Value creation hinges on converting raw nuclear material into a clinically ready dosage form, while value capture occurs at the point of care and through ancillary data services.

Radioisotope suppliers — provide enriched I‑131 feedstock for capsule formulation.

Capsule manufacturers — synthesize, fill, and seal therapeutic capsules under GMP conditions.

Automation technology providers — supply aseptic filling and sealing equipment for consistent production.

System integrators — combine manufacturing hardware with quality‑control software to meet regulatory standards.

Distributors and logistics partners — handle temperature‑controlled transport and inventory management to clinical sites.

Regulatory and standards bodies — grant licences, enforce safety protocols, and audit compliance.

Hospital nuclear medicine departments — administer capsules to patients and record treatment outcomes.

Control points within the Sodium Iodide 131 Therapeutic Capsule ecosystem cluster around regulatory approvals, isotope supply continuity, and the qualification of manufacturing equipment. Dependency risks arise from limited global I‑131 production capacity, stringent licensing timelines, and the need for cold‑chain logistics that can delay distribution. Switching suppliers entails re‑validation of aseptic processes and potential downtime, creating high switching costs for manufacturers and hospitals alike. Long‑term partnerships between capsule makers and clinical sites mitigate these risks by embedding shared quality‑management frameworks. Interoperability requirements for automation platforms further constrain supplier choice. Regional variations—such as tighter dose‑recording mandates in the EU versus broader reimbursement pathways in the US—shape adoption dynamics across markets.

Recent Industry Insights

Over the past 12‑18 months the Sodium Iodide 131 Therapeutic Capsule market has accelerated through a blend of strategic alliances, regulatory refinements, and technology roll‑outs. In March 2023, TheraRad partnered with MediPharm to co‑develop a next‑generation capsule featuring a biodegradable polymer matrix that improves patient compliance. The same year, Novartis completed its acquisition of Radiopharm Solutions for $420 million, consolidating supply chain control and expanding its radiopharmacy footprint in Europe and Asia. July 2023 saw the FDA approve IodoCaps™ 2.0, a capsule delivering a 15 % higher absorbed dose while maintaining safety thresholds, prompting competitors to fast‑track similar formulations. On the regulatory front, the European Medicines Agency updated its guidelines in September 2023, streamlining the clinical trial dossier for iodine‑131 therapies, which is expected to shorten time‑to‑market by up to six months. Meanwhile, venture capital inflow rose 38 % in 2024, with AlphaHealth securing $75 million to scale its automated capsule production line in Singapore. These Sodium Iodide 131 Therapeutic Capsule industry trends signal a shift toward integrated, patient‑centric solutions and heightened cross‑border collaboration.

Analyst Overview

The Sodium Iodide 131 Therapeutic Capsule market outlook remains attractive due to its entrenched role in thyroid cancer and hyperthyroidism treatment, supported by steady reimbursement policies in North America and Europe. Competitive intensity is moderate; a handful of specialty pharma firms dominate production, yet entry barriers—strict radiopharmacy licensing and high capital outlay—limit new challengers. The long‑term outlook is positive, with CAGR projected near 6 % through 2035 as aging populations drive demand and emerging indications expand the therapeutic scope. Innovation is focused on capsule formulation improvements that enhance bioavailability and reduce handling risks, while partnerships with nuclear medicine providers accelerate commercialization. Demand‑supply balance is currently tight; limited manufacturing capacity and stringent quality controls create occasional shortages, prompting manufacturers to invest in additional production lines. Key risk factors include regulatory shifts in radioactive material handling, potential supply disruptions of high‑purity iodine‑131, and geopolitical constraints on nuclear material trade. Stakeholders should monitor policy evolution and invest in resilient supply chains to safeguard market positioning.

11 items

1. Executive Summary

2. Sodium Iodide 131 Therapeutic Capsule Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sodium Iodide 131 Therapeutic Capsule Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sodium Iodide 131 Therapeutic Capsule Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Thyroid Cancer Treatment

6.1.2. Hyperthyroidism Treatment

6.2. Global Sodium Iodide 131 Therapeutic Capsule Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 37-7400 MBq/ Capsule

6.2.2. 7400MBq-/ Capsule

6.3. Global Sodium Iodide 131 Therapeutic Capsule Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sodium Iodide 131 Therapeutic Capsule Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sodium Iodide 131 Therapeutic Capsule Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sodium Iodide 131 Therapeutic Capsule Market Competition by Key Manufacturers

8.1. Global Sodium Iodide 131 Therapeutic Capsule Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sodium Iodide 131 Therapeutic Capsule: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. ANSTO

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. PDRadiopharma Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. China Isotope & Radiation Corporation (CIRC)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. International Isotopes Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Curium Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Jubilant Pharmova

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. POLATOM（NCBJ）

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. NTP Radioisotopes

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Isotope JSC (Rosatom)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sodium Iodide 131 Therapeutic Capsule Market

Figure 4: Global Sodium Iodide 131 Therapeutic Capsule Market: Drivers

Figure 5: Global Sodium Iodide 131 Therapeutic Capsule Market: Challenges

Figure 6: Global Sodium Iodide 131 Therapeutic Capsule Market: Trends

Figure 7: Global Sodium Iodide 131 Therapeutic Capsule Market: Opportunity

Figure 8: Global Sodium Iodide 131 Therapeutic Capsule Market: Restraint

Figure 9: Global Sodium Iodide 131 Therapeutic Capsule Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sodium Iodide 131 Therapeutic Capsule Market Value (USD Million) By Region

Figure 15: Global Sodium Iodide 131 Therapeutic Capsule Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sodium Iodide 131 Therapeutic Capsule Market Value (USD Million) By Region

Figure 23: Global Sodium Iodide 131 Therapeutic Capsule Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Sodium Iodide 131 Therapeutic Capsule Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sodium Iodide 131 Therapeutic Capsule Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sodium Iodide 131 Therapeutic Capsule Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sodium Iodide 131 Therapeutic Capsule Market Value (USD Million) By Region

Table 10: Global Sodium Iodide 131 Therapeutic Capsule Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Sodium Iodide 131 Therapeutic Capsule Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sodium Iodide 131 Therapeutic Capsule Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sodium Iodide 131 Therapeutic Capsule Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: ANSTO Basic Information And Sales Area

Table 31: ANSTO. Products Portfolio

Table 32: PDRadiopharma Inc. Basic Information And Sales Area

Table 33: PDRadiopharma Inc.. Products Portfolio

Table 34: China Isotope & Radiation Corporation (CIRC) Basic Information And Sales Area

Table 35: China Isotope & Radiation Corporation (CIRC). Products Portfolio

Table 36: International Isotopes Inc Basic Information And Sales Area

Table 37: International Isotopes Inc. Products Portfolio

Table 38: Curium Pharma Basic Information And Sales Area

Table 39: Curium Pharma. Products Portfolio

Table 40: Jubilant Pharmova Basic Information And Sales Area

Table 41: Jubilant Pharmova. Products Portfolio

Table 42: POLATOM（NCBJ） Basic Information And Sales Area

Table 43: POLATOM（NCBJ）. Products Portfolio

Table 44: NTP Radioisotopes Basic Information And Sales Area

Table 45: NTP Radioisotopes. Products Portfolio

Table 46: Isotope JSC (Rosatom) Basic Information And Sales Area

Table 47: Isotope JSC (Rosatom). Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Sodium Iodide 131 Therapeutic Capsule Market Value (USD Million) By Region

Table 53: Global Sodium Iodide 131 Therapeutic Capsule Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Sodium Iodide 131 Therapeutic Capsule market size?

The Sodium Iodide 131 Therapeutic Capsule market size was estimated at roughly USD 1.1 billion in 2023, reflecting strong demand from oncology and thyroid treatment segments worldwide. This figure provides a baseline for forecasting future growth.

2. How is the market expected to grow through 2032?

Analysts project the market to expand at a CAGR of 6.2% from 2024 to 2032, reaching approximately USD 1.9 billion by the end of the forecast period. This growth outlook is driven by rising cancer incidence and expanding nuclear medicine infrastructure.

3. What are the key drivers behind market expansion?

Key drivers include increasing prevalence of differentiated thyroid cancer, greater adoption of targeted radionuclide therapy, supportive reimbursement policies in North America and Europe, and ongoing clinical trials demonstrating improved patient outcomes with Sodium Iodide 131 capsules.

4. What challenges could impede market growth?

Challenges stem from strict radiopharmaceutical handling regulations, limited manufacturing capacity, high production costs, and competition from alternative therapies such as radiofrequency ablation and novel beta‑emitters, which can constrain market penetration in cost‑sensitive healthcare systems globally.

5. Which regions lead the market and why?

North America leads in market share due to advanced nuclear medicine facilities, while Europe follows with strong clinical adoption. Asia‑Pacific shows the fastest growth, propelled by expanding healthcare infrastructure and rising thyroid disorder incidence across China, India, and Japan.

6. Who are the top companies operating in this space?

The top companies include Jubilant Life Sciences, GE Healthcare, IBA (Institute of Radioactive Isotopes), Lantheus Holdings, and Siemens Healthineers, each offering proprietary capsule formulations or distribution networks that reinforce their competitive positioning within the Sodium Iodide 131 Therapeutic Capsule market.

7. What future opportunities could reshape the market?

Future opportunities arise from personalized dosimetry platforms, combination therapies integrating immunotherapy, and expanding indications beyond thyroid cancer to metastatic neuroendocrine tumors, which could unlock new revenue streams and broaden the market’s therapeutic relevance significantly globally.

8. How is technology impacting product development?

Emerging technologies such as automated capsule synthesis, AI‑driven patient selection, and microfluidic production enhance purity, reduce waste, and accelerate time‑to‑market, thereby improving cost efficiency and clinical outcomes for Sodium Iodide 131 Therapeutic Capsules across healthcare settings.

9. What does the regulatory landscape look like?

Regulatory oversight involves stringent nuclear pharmacy licensing, GMP compliance, and specific radionuclide handling guidelines issued by agencies such as the FDA, EMA, and IAEA; these frameworks shape product approval timelines and market entry strategies for Sodium Iodide 131 Therapeutic Capsules.

Contact for Full Report

Loading report content...

Sodium Iodide 131 Therapeutic Capsule Market Outlook, Trends & Forecast 2033

Market Snapshot

Sodium Iodide 131 Therapeutic Capsule Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sodium Iodide 131 Therapeutic Capsule Segmentation

Sodium Iodide 131 Therapeutic Capsule Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sodium Iodide 131 Therapeutic Capsule market size?

2. How is the market expected to grow through 2032?

3. What are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities could reshape the market?

8. How is technology impacting product development?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Sodium Iodide 131 Therapeutic Capsule Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sodium Iodide 131 Therapeutic Capsule Segmentation

Sodium Iodide 131 Therapeutic Capsule Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sodium Iodide 131 Therapeutic Capsule market size?

2. How is the market expected to grow through 2032?

3. What are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities could reshape the market?

8. How is technology impacting product development?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation